Protagenic Therapeutics Inc (NASDAQ:PTIX)’s traded shares stood at 0.44 million during the last session. At the last check today, the stock’s price was $0.28, to imply a decrease of -3.54% or -$0.01 in intraday trading. The PTIX share’s 52-week high remains $1.87, putting it -567.86% down since that peak but still an impressive 14.29% since price per share fell to its 52-week low of $0.24.

Protagenic Therapeutics Inc (NASDAQ:PTIX) trade information

After registering a -3.54% downside in the latest session, Protagenic Therapeutics Inc (PTIX) has traded red over the past five days. The 5-day price performance for the stock is 4.67%, and -33.55% over 30 days. With these gigs, the year-to-date price performance is -43.29%.

PTIX Dividends

Protagenic Therapeutics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Protagenic Therapeutics Inc (NASDAQ:PTIX)’s Major holders

We also have Vanguard Extended Market Index Fund and Fidelity NASDAQ Composite Index Fund as the top two Mutual Funds with the largest holdings of the Protagenic Therapeutics Inc (PTIX) shares. Going by data provided on Sep 30, 2024, Vanguard Extended Market Index Fund holds roughly 32.0 shares. This is just over 0.44% of the total shares, with a market valuation of $9282.0. Data from the same date shows that the other fund manager holds a little less at 22.88, or 0.32% of the shares, all valued at about 6637.0.